ERBB2 and breast cancer: The distribution of primary breast cancer subtypes was as follows: Hormone receptor (HR) positive without HER2 amplification or overexpression 66.1% (n = 210), HR-negative without HER2 amplification or overexpression (triple negative) 12.9% (n = 41), HER2-positive: 21% (n = 67).